Apres IOM, le Deluge! Posted: September 27, 2006 FDA's Division of Drug Marketing, Advertising & Communication (DDMAC) has added a second DTC review group to meet soaring demand for advertising approvals, reports MM&M. "The number of DTC ads submitted is expected to climb again for 2006." You think? The drug industry is swamping the FDA with DTC ads for pre-approval. How many DTC and professional promotional pieces does the FDA review each year? How many DTC ads will be submitted to the FDA for review in 2006? Can the handful of additional staff handle the workload? For answers to these and other questions, read today's post to Pharma Marketing Blog. For more posts in related topic areas, see: Drug Safety FDA DTC Advertising If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe. Enter your Email Address | Return to Pharma Marketing Blog Topics |

Special Supplement eDetailing This Special Supplement to Pharma Marketing News brings together in one convenient document several topics and case studies on eDetailing and ePromotion to physicians. The resultant collective wisdom of many experts both inside pharmaceutical companies and outside provide a frank assessment of the role and impact of eDetailing on physician marketing as well as the challenges that lie ahead. INCLUDES THESE BONUS REPRINTS: Beyond the eDetail: Evolving to Educate eDetailing: Yesterday, Today and Tomorrow TABLE OF CONTENTS REDUCED PRICE! ONLY $19.95 Order and pay for this Special Supplement now using your credit card. PDF file delivered to you by email (usually within minutes of placing your order): If you wish to be pay by check or credit card off-line, please use: Printable Order Form